Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07476807

Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Rash Exanthema Skin Diseases Skin and Connective Tissue Diseases Systemic Treatments Tele-assessment

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sligo university Hospital

Sligo, f91h684, Ireland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must meet all of the following criteria:

  • Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT).
  • New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT.
  • Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria.
  • Clinically stable condition not requiring urgent in-person evaluation.
  • Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.

Exclusion criteria

Participants will be excluded if any of the following criteria apply:

  • Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria.
  • Clinical status requiring urgent or immediate face-to-face medical assessment.
  • Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects.
  • Inability to access or effectively use the required telemedicine technology.

Treatment and study plan

telem healthassessment

Other

SOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders

Primary outcomes

  1. time to clinical resolution

    Time frame: 6 weeks

    Number of days from first AHOS contact to documented resolution (Grade 0-1).

Secondary outcomes

  1. Escalation in person review

    Time frame: 6 weeks

    Proportion of telemedicine patients requiring:

    • Conversion to face-to-face review
    • Emergency department attendance
    • Hospital admission

  2. treatment modification reat

    Time frame: 6 weeks

    Proportion of telemedicine patients requiring:

    • Conversion to face-to-face review
    • Emergency department attendance
    • Hospital admission

  3. unscheduled acute contact

    Time frame: 6 weeks

    Number of unplanned re-contacts with AHOS

  4. Patient-Reported Endpoints -Quality of Life (QoL) and patient satisfaction

    Time frame: 6 weeks

    Instrument:

    QLQ administered:

    • Post initial assessment
    • At resolution or week 6

Sponsors and collaborators

Lead sponsor

Sligo General Hospital

Other

Registry information

Official study title

TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

Acronym: TREATS

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 17, 2026
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.